Lasa Supergenerics Limited (LASA) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.005x

Based on the latest financial reports, Lasa Supergenerics Limited (LASA) has a cash flow conversion efficiency ratio of 0.005x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rs2.59 Million ≈ $27.98K USD) by net assets (Rs563.42 Million ≈ $6.09 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Lasa Supergenerics Limited - Cash Flow Conversion Efficiency Trend (2017–2025)

This chart illustrates how Lasa Supergenerics Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read debt load of Lasa Supergenerics Limited for a breakdown of total debt and financial obligations.

Lasa Supergenerics Limited Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Lasa Supergenerics Limited ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Celtic plc
LSE:CCPC
-0.038x
Binani Industries Limited
NSE:BINANIIND
0.019x
Zenvia Inc
NASDAQ:ZENV
-0.034x
Groupe JAJ
PA:GJAJ
0.016x
The Dixie Group Inc
NASDAQ:DXYN
0.084x
MOVIE GAMES S.A. ZY1
F:2LH
0.070x
NCL International Logistics Public Company Limited
BK:NCL
-0.560x
Gungnir Resources Inc
V:GUG
-0.034x

Annual Cash Flow Conversion Efficiency for Lasa Supergenerics Limited (2017–2025)

The table below shows the annual cash flow conversion efficiency of Lasa Supergenerics Limited from 2017 to 2025. For the full company profile with market capitalisation and key ratios, see Lasa Supergenerics Limited (LASA) total market value.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-03-31 Rs837.13 Million
≈ $9.05 Million
Rs-28.24 Million
≈ $-305.37K
-0.034x -252.47%
2024-03-31 Rs966.76 Million
≈ $10.46 Million
Rs21.39 Million
≈ $231.29K
0.022x +115.13%
2023-03-31 Rs1.18 Billion
≈ $12.79 Million
Rs-173.00 Million
≈ $-1.87 Million
-0.146x -350.68%
2022-03-31 Rs1.58 Billion
≈ $17.07 Million
Rs92.12 Million
≈ $996.20K
0.058x -77.56%
2021-03-31 Rs1.59 Billion
≈ $17.19 Million
Rs413.10 Million
≈ $4.47 Million
0.260x +169.95%
2020-03-31 Rs1.41 Billion
≈ $15.30 Million
Rs136.23 Million
≈ $1.47 Million
0.096x -75.06%
2019-03-31 Rs1.05 Billion
≈ $11.39 Million
Rs406.58 Million
≈ $4.40 Million
0.386x +12.48%
2018-03-31 Rs1.17 Billion
≈ $12.69 Million
Rs402.80 Million
≈ $4.36 Million
0.343x +962.97%
2017-03-31 Rs754.94 Million
≈ $8.16 Million
Rs-30.03 Million
≈ $-324.76K
-0.040x --

About Lasa Supergenerics Limited

NSE:LASA India Drug Manufacturers - Specialty & Generic
Market Cap
$4.33 Million
Rs400.81 Million INR
Market Cap Rank
#28631 Global
#1612 in India
Share Price
Rs8.00
Change (1 day)
-1.23%
52-Week Range
Rs5.67 - Rs18.47
All Time High
Rs206.80
About

Lasa Supergenerics Limited engages in the research, manufacture, and marketing of animal and human healthcare products in India. It offers API bulk drug products comprising fenbendazole, toldimphos sodium, cyromazine, albendazole, ricobendazole, triciabendazole, oxfendazole, closantel base, closantel sodium dihydrate BP, nitroxynil, rafoxanide, oxyclozanide, ornidazole, halquinol, and 2,6-diiodo-… Read more